"Over the years, novel therapeutics developed at Genentech have extended patients’ life span and improved their quality of life. It’s incredibly rewarding to be a part of it. I am energized everyday to be working alongside so many talented scientists that are dedicated to bringing safe and efficacious drugs to patients."
I joined Genentech in 2006 as a Scientist in the Safety Assessment Department. I’ve had the opportunity to design and lead the nonclinical safety strategies of many programs spanning from early discovery to post-marketing, and on a diverse platform of molecules including therapeutic antibodies, antibody-drug conjugates, and small molecules. Our study results are used to support clinical development and registration of these novel therapeutics. Our science-based, innovative approaches have enabled us to continue to bring novel drugs forward and advance the science of preclinical safety evaluation. Currently I am responsible for overall preclinical safety strategy and deliverables of the oncology programs. I’ve also had the opportunities to lead Pharmacology Subteams where I am ultimately responsible for overall preclinical development strategies.
I received MD in 1990 and PhD in 1997. I found my passion in drug development and translational safety evaluation, and have worked in biotechnology and pharmaceutical companies for almost 18 years.
Toxicol Pathol. 2012;40(2):272-87.
We utilize integrated and cutting-edge in vitro and in vivo models to characterize the safety profile of novel therapeutics to inform clinical dose selection, safety monitoring, and benefit/risk evaluation. Patients’ safety is our No. 1 goal. We also actively drive innovation in preclinical drug development approaches to enhance the clinical predictivity of preclinical safety findings, support cross-industry efforts to increase drug development efficiency and success, and ultimately deliver safer and more efficacious drugs to patients. My expertise and research interest are in oncology, cancer immunotherapy and immunology.